收费全文 | 18224篇 |
免费 | 1079篇 |
国内免费 | 32篇 |
耳鼻咽喉 | 258篇 |
儿科学 | 491篇 |
妇产科学 | 277篇 |
基础医学 | 2352篇 |
口腔科学 | 639篇 |
临床医学 | 1595篇 |
内科学 | 3508篇 |
皮肤病学 | 355篇 |
神经病学 | 2120篇 |
特种医学 | 1201篇 |
外国民族医学 | 1篇 |
外科学 | 2598篇 |
综合类 | 155篇 |
一般理论 | 4篇 |
预防医学 | 1589篇 |
眼科学 | 350篇 |
药学 | 853篇 |
中国医学 | 14篇 |
肿瘤学 | 975篇 |
2022年 | 119篇 |
2021年 | 281篇 |
2020年 | 175篇 |
2019年 | 227篇 |
2018年 | 309篇 |
2017年 | 255篇 |
2016年 | 284篇 |
2015年 | 334篇 |
2014年 | 473篇 |
2013年 | 585篇 |
2012年 | 837篇 |
2011年 | 872篇 |
2010年 | 543篇 |
2009年 | 493篇 |
2008年 | 831篇 |
2007年 | 932篇 |
2006年 | 855篇 |
2005年 | 824篇 |
2004年 | 738篇 |
2003年 | 710篇 |
2002年 | 694篇 |
2001年 | 637篇 |
2000年 | 593篇 |
1999年 | 486篇 |
1998年 | 203篇 |
1997年 | 143篇 |
1996年 | 122篇 |
1995年 | 161篇 |
1994年 | 134篇 |
1993年 | 121篇 |
1992年 | 337篇 |
1991年 | 365篇 |
1990年 | 307篇 |
1989年 | 288篇 |
1988年 | 265篇 |
1987年 | 231篇 |
1986年 | 254篇 |
1985年 | 255篇 |
1984年 | 202篇 |
1983年 | 183篇 |
1982年 | 127篇 |
1981年 | 122篇 |
1979年 | 238篇 |
1978年 | 155篇 |
1977年 | 149篇 |
1975年 | 147篇 |
1974年 | 128篇 |
1973年 | 135篇 |
1972年 | 141篇 |
1970年 | 117篇 |
Background
Resistin is an immunometabolic mediator that is elevated in several inflammatory disorders. A ligand for Toll-like receptor 4, resistin modulates the recruitment and activation of myeloid cells, notably neutrophils. Neutrophils are major drivers of cystic fibrosis (CF) lung disease, in part due to the release of human neutrophil elastase- and myeloperoxidase-rich primary granules, leading to tissue damage. Here we assessed the relationship of resistin to CF lung disease.Methods
Resistin levels were measured in plasma and sputum from three retrospective CF cohorts spanning a wide range of disease. We also assessed the ability of neutrophils to secrete resistin upon activation in vitro. Finally, we constructed a multivariate model assessing the relationship between resistin levels and lung function.Results
Plasma resistin levels were only marginally higher in CF than in healthy control subjects. By contrast, sputum resistin levels were very high in CF, reaching 50–100 fold higher levels than in plasma. Among CF patients, higher plasma resistin levels were associated with allergic bronchopulmonary aspergillosis, and higher sputum resistin levels were associated with CF-related diabetes. Mechanistically, in vitro release of neutrophil primary granules was concomitant with resistin secretion. Overall, sputum resistin levels were negatively correlated with CF lung function, independently of other variables (age, sex, and genotype).Conclusions
Our data establish relationships between resistin levels in the plasma and sputum of CF patients that correlate with disease status, and identify resistin as a novel mechanistic link between neutrophilic inflammation and lung disease in CF. 相似文献Areas covered: This review focuses on current treatments and the future outlook for allergic rhinitis. Pharmacotherapy includes mast cell stabilizers, antihistamines, glucocorticosteroids (GCSs), leukotriene receptor antagonists, and nasal decongestants. Nasal GCSs are currently regarded as the most effective treatment and are considered first-line therapy together with non-sedating antihistamines. The new formulation MP29-02 combines the nasal GCS fluticasone propionate with azelastine in one single spray and has achieved greater improvements than those under monotherapy with modern GCSs or antihistamines. Furthermore, this review discusses allergen immunotherapy alone and in combination with modern monoclonal antibodies.
Expert opinion: Despite the variety of medications for allergic rhinitis, ranging from general symptomatic agents like GCSs or decongestants, to more specific ones like histamine receptor or leukotriene blockers, to causal therapy like immunotherapy, many patients still experience treatment failures or unsatisfactory results. The ultimate goal may be to endotype every downstream pathway separately in order to offer patients individualized, targeted therapy with specific antibodies against the respective pathway. 相似文献
Methods: A retrospective cohort study of patients with IU who had a minimal follow-up of one year.
Results: 96 patients (174 eyes, 70% females) were included with a mean age at presentation of 30 years. Children constituted 38% of all patients. Mean follow- up was 64.9 months. Pars planitis was the most common form followed by sarcoidosis and multiple sclerosis. Cystoid macular edema (CME), cataract, epiretinal membrane and posterior synechiae were the most prevalent complications. Posterior synechiae, band keratopathy, cataract and papillitis at presentation were associated with worse presenting visual acuity (VA). Of the late-onset complications, glaucoma/ocular hypertension (OHT) was the most significantly associated with worse long-term VA. Most sight-threatening complications (namely CME and glaucoma) were diagnosed at presentation while late complications predominantly affected the posterior segment and included among others peripheral retinal elevations, vasoproliferative tumors, and vitreous hemorrhage. Median LogMAR VA improved at short-term and long-term follow-up, from 0.2 to 0.1 (p<0.001). Subgroup analysis revealed significant VA improvement for eyes with all the different complications except for eyes with glaucoma/OHT.
Conclusion: IU is a chronic low-grade uveitis that may be associated with protean early and late complications of the anterior or posterior segments or both. Optimal treatment regimens are imperative for the strict control of inflammation and proper management of complications thus allowing a favorable long-term prognosis. 相似文献